Biocon Biologics settles patent issue; paves way for launch of biosimilar product in Canada

Biocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalmology product for neovascular and age-related macular degeneration, in Canada by July 1, 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YGviHOK
via IFTTT